Taxus Cardium Pharmaceuticals Group, Inc. (CRXM) financial statements (2021 and earlier)

Company profile

Business Address 11750 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10002
Cash and cash equivalents10002
Receivables    0
Inventory, net of allowances, customer advances and progress billings  001
Inventory  001
Prepaid expense and other current assets0
Other undisclosed current assets00(0)00
Total current assets:10004
Noncurrent Assets
Property, plant and equipment00000
Long-term investments and receivables  020
Long-term investments  020
Intangible assets, net (including goodwill)   2
Goodwill    1
Intangible assets, net (excluding goodwill)    1
Deposits noncurrent assets   0 
Other noncurrent assets0 00
Prepaid expense and other noncurrent assets0
Other undisclosed noncurrent assets    1
Total noncurrent assets:00024
TOTAL ASSETS:10138
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities33221
Accounts payable22111
Accrued liabilities21111
Employee-related liabilities  0  
Due to related parties11   
Other undisclosed current liabilities  0  
Total current liabilities:44221
Noncurrent Liabilities
Liabilities, other than long-term debt0   0
Deferred revenue and credits0   0
Total noncurrent liabilities:0   0
Total liabilities:44221
Stockholders' equity
Stockholders' equity attributable to parent(3)(4)(2)16
Common stock00000
Common stock, value, subscriptions11 
Additional paid in capital114111109107103
Accumulated deficit(117)(115)(111)(105)(96)
Stockholders' equity attributable to noncontrolling interest(0)    
Total stockholders' equity:(3)(4)(2)16
TOTAL LIABILITIES AND EQUITY:10138

Income statement (P&L) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
   01
Cost of revenue(0)(0)(0)(0)(0)
Cost of goods and services sold(0)(0)(0)0(0)
Gross profit:(0)(0)(0)00
Operating expenses(3)(3)(4)(7)(9)
Other undisclosed operating income000  
Operating loss:(3)(3)(4)(7)(8)
Nonoperating income (expense)(0)(1)(2)00
Investment income, nonoperating   00
Other nonoperating expense(0)(1)(2)  
Interest and debt expense(0)(0)(0)(0)(0)
Loss from continuing operations before income taxes:(3)(4)(6)(7)(8)
Income tax benefit  924
Income (loss) before gain (loss) on sale of properties:(3)(4)3(5)(4)
Other undisclosed net income0    
Net income (loss):(3)(4)3(5)(4)
Net income attributable to noncontrolling interest0    
Other undisclosed net income (loss) attributable to parent 0(9)(4)(4)
Net loss attributable to parent:(3)(4)(6)(9)(8)
Preferred stock dividends and other adjustments(1)(1) (0) 
Net loss available to common stockholders, diluted:(4)(4)(6)(9)(8)

Comprehensive Income ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss):(3)(4)3(5)(4)
Comprehensive income (loss):(3)(4)3(5)(4)
Comprehensive income, net of tax, attributable to noncontrolling interest0    
Comprehensive income (loss), net of tax, attributable to parent:(3)(4)3(5)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: